Company News 

Pricing pressure dampens global pharma sentiment

Pricing pressure dampens global pharma sentiment

The launch of a top-selling drug has historically been enough to satisfy the shareholders of big pharmaceutical companies. In 2017, it seems that will no longer do. Merck (US: MRK) and Shire(SHP) have both recently launched blockbuster drugs – generating over $1bn of sales in one year – in the US, but suffered heavy share price declines after reporting lower than expected revenue in their respective third quarters.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now